[HTML][HTML] Response to nivolumab in metastatic collecting duct carcinoma expressing PD‑L1: A case report
K Mizutani, K Horie, S Nagai… - Molecular and …, 2017 - spandidos-publications.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD‑1) immune‑checkpoint‑inhibitor antibody, following …
nivolumab, a programmed death 1 (PD‑1) immune‑checkpoint‑inhibitor antibody, following …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
K Mizutani, K Horie, S Nagai… - Molecular and …, 2017 - pubmed.ncbi.nlm.nih.gov
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
K MIZUTANI, K HORIE, S NAGAI… - Molecular & Clinical …, 2017 - search.ebscohost.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
K Mizutani, K Horie, S Nagai… - Molecular and …, 2017 - search.proquest.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
K Mizutani, K Horie, S Nagai, T Tsuchiya… - Molecular and Clinical …, 2017 - go.gale.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
[引用][C] Response to nivolumab in metastatic collecting duct carcinoma expressing PD‐L1: a case report
K Mizutani - Mol. Clin. Oncol., 2017 - cir.nii.ac.jp
Response to nivolumab in metastatic collecting duct carcinoma expressing PD‐L1: a case
report | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
report | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
K Mizutani, K Horie, S Nagai, T Tsuchiya… - … and Clinical Oncology, 2017 - europepmc.org
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
Response to nivolumab in metastatic collecting duct carcinoma expressing PD‑L1: A case report
K MIZUTANI, K HORIE, S NAGAI, T TSUCHIYA… - ingentaconnect.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD1) immunecheckpointinhibitor antibody, following the …
nivolumab, a programmed death 1 (PD1) immunecheckpointinhibitor antibody, following the …
[HTML][HTML] Response to nivolumab in metastatic collecting duct carcinoma expressing PD‑L1: A case report
K Mizutani, K Horie, S Nagai… - Molecular and …, 2017 - spandidos-publications.com
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD‑1) immune‑checkpoint‑inhibitor antibody, following …
nivolumab, a programmed death 1 (PD‑1) immune‑checkpoint‑inhibitor antibody, following …
[HTML][HTML] Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
K Mizutani, K Horie, S Nagai, T Tsuchiya… - … and Clinical Oncology, 2017 - ncbi.nlm.nih.gov
The authors present a case report of collecting duct carcinoma (CDC) that responded to
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …
nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following …